NASDAQ: BGMBgm Group Ltd Stock
$10.52-0.48 (-4.36%)
Updated Apr 21, 2025
BGM Price
$10.52
Fair Value Price
N/A
Market Cap
$76.01M
52 Week Low
$2.70
52 Week High
$14.78
P/E
-52.59x
P/B
1.78x
P/S
2.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$25.10M
Earnings
-$1.44M
Gross Margin
16.4%
Operating Margin
-5.67%
Profit Margin
-5.7%
Debt to Equity
0.21
Operating Cash Flow
$544k
Beta
0.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BGM Overview
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BGM's potential to beat the market
- BGM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
BGM
RankedUnranked of 54
RankedUnranked of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.13 | A | |
| $13.89 | A | |
| $30.29 | A |
Be the first to know about important BGM news, forecast changes, insider trades & much more!
BGM News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BGM scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BGM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BGM is good value based on its book value relative to its share price (1.78x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.98x)
P/B vs Industry Valuation
BGM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more BGM due diligence checks available for Premium users.
Valuation
BGM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-52.59x
Industry
20.59x
Market
27.14x
BGM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.78x
Industry
1.98x
BGM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BGM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BGM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BGM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$53.0M
Liabilities
$8.9M
Debt to equity
0.21
BGM's short-term assets ($29.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BGM's short-term assets ($29.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BGM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BGM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BGM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BGM vs Pharmaceutical Stocks
Bgm Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.